Recent biotech ETF inflows could positively impact the ARQT stock forecast, as passive allocation boosts demand. However, macro headwinds like rate hikes could dampen gains. Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) stock has received a consensus rating of “Moderate Buy”. Meanwhile, the price target for the stock stands at $13.33, representing a potential upside of around 40% from the current price levels. We just received data on a new analyst forecast for $ARQT. Needham gave a rating of 'Buy' for $ARQT. ARQT stock forecast shows mixed sentiment as analysts weigh recent earnings softness against upcoming clinical milestones. Trading near $7.20, the biotech player’s volatility remains high, with implied options volatility over 60%. Investors eye 2024 trial readouts as potential catalysts for a breakout.